BioXcel Therapeutics, Inc. (BTAI) analyst actions
Rating and price-target actions on BTAI in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the BTAI overview →
1 measured BTAI analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia | Press release | +0.70% | -3.26% |
Keep exploring
More BTAI: earnings → · SEC filings → · BTAI overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| OHR PHARMACEUTICALS (OHRP) | 393 | 0.00% | 48% |
| ACADIA Pharmaceuticals Inc. (ACAD) | 392 | -0.14% | 43% |
| Karyopharm Therapeutics Inc. (KPTI) | 392 | -0.45% | 45% |
| Rubius Therapeutics, Inc. (RUBY) | 392 | -0.32% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.